http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2491649-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18b20240f5eb92249e3488c2d05a70cf |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F17-00 |
| filingDate | 2003-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a86467a65d58a6ec0bf9e264cadcc506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5bf208e83aaa65f865d9c626977e137 |
| publicationDate | 2004-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2491649-A1 |
| titleOfInvention | Functionalised metallocenes as anticancer drugs |
| abstract | The invention provides metallocene compounds of formula (1) for use as medicaments in the treatment of cancer. Formula (1) wherein R1, R2, R3 and R4 represent a combination of H, alkyl, aryl or trimethylsilyl; L represents side chain substituents, at least one of which contains a group which enables the compound to become water-solubilised; X is halo, alkoxy, acetate or H2O; Y is a counter-ion; and M is a metal. The invention also provides novel compounds of the formula (1) wherein at least one of the groups L comprises aquaternary tetraalkylammonium group. The compounds have been shown to have significantly greater activity in the treatment of cancer than the compounds known from the prior art. |
| priorityDate | 2002-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.